Patents Assigned to Abbott GmbH & Co. KG
-
Publication number: 20060270606Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L ??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: ApplicationFiled: April 18, 2006Publication date: November 30, 2006Applicant: Abbott GmbH & Co., KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Publication number: 20060257470Abstract: The invention concerns a method for producing solid galenic formulations which consists in: forming a processable paste comprising a) 50 to 99.4 wt. % of at least one non-thermoplastic carrier, b) 0.5 to 30 wt. % of at least an adjuvant selected among thermoplastic polymers, lipids, sugar alcohols and solubilizing agents, c) 0.1 to 49.5 wt. % of at least one active principle, at a temperature not less than the softening temperature of the adjuvant but rising to at least 70° C.; then in cooling the resulting paste. Said solid galenic formulations quickly disintegrate in an aqueous medium.Type: ApplicationFiled: October 9, 2003Publication date: November 16, 2006Applicant: Abbott GmbH & Co. KGInventors: Joerg Rosenberg, Gunther Berndl, Markus Magerlein
-
Patent number: 7125883Abstract: The invention relates to novel compounds which bind to integrin receptors, to their preparation, to their use as integrin receptor ligands and for treating diseases, to pharmaceutical preparations comprising these compounds, and to pharmaceutical preparations comprising at least one other active compound.Type: GrantFiled: March 29, 2000Date of Patent: October 24, 2006Assignee: Abbott GmbH & Co. KGInventors: Johann-Christian Zechel, Andreas Kling, Herve Geneste, Udo Lange, Arnulf Lauterbach, Claudia Isabella Graef, Thomas Subkowski, Jens Sadowski, Wilfried Hornberger
-
Patent number: 7119097Abstract: A compound of the formula pharmaceutically acceptable salts and enantiomers thereof and pharmaceutical compositions containing this compound, its pharmaceutically acceptable salts and enantiomers are claimed.Type: GrantFiled: March 16, 2006Date of Patent: October 10, 2006Assignee: Abbott GmbH & Co. KGInventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Muller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack
-
Patent number: 7109205Abstract: Carboxylic acid derivatives where R–R6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.Type: GrantFiled: June 24, 2003Date of Patent: September 19, 2006Assignee: Abbott GmbH & Co. KGInventors: Hartmut Riechers, Dagmar Klinge, Wilhelm Amberg, Andreas Kling, Stefan Müller, Ernst Baumann, Joachim Rheinheimer, Uwe Josef Vogelbacher, Wolfgang Wernet, Liliane Unger, Manfred Raschack
-
Patent number: 7105508Abstract: The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.Type: GrantFiled: August 1, 2000Date of Patent: September 12, 2006Assignee: Abbott GmbH & Co. KGInventors: Andreas Kling, Hervé Geneste, Udo Lange, Arnulf Lauterbach, Claudia Isabella Graef, Thomas Subkowski, Uta Holzenkamp, Helmut Mack, Jens Sadowski, Wilfried Hornberger, Volker Laux
-
Patent number: 7098214Abstract: Dopamine D3 receptor ligands or antagonists are disclosed for use in the treatment of renal function disorders, such as diabetic nephropathy.Type: GrantFiled: April 28, 2000Date of Patent: August 29, 2006Assignee: Abbott GmbH & Co. KGInventors: Bernd Mühlbauer, Gerhard Gross, Dorothea Starck, Hans-Jörg Treiber
-
Patent number: 7091227Abstract: The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.Type: GrantFiled: February 6, 2001Date of Patent: August 15, 2006Assignee: Abbott GmbH & Co. KGInventors: Barbara Scott, Lee D. Arnold, Anna M. Ericsson, Kevin P. Cusack
-
Patent number: 7084110Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L,??(I) and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.Type: GrantFiled: September 25, 2002Date of Patent: August 1, 2006Assignee: Abbott GmbH & Co., KGInventors: Bernd Janssen, Teresa Barlozzari, Andreas Haupt, Thomas Zierke, Andreas Kling
-
Publication number: 20060134196Abstract: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.Type: ApplicationFiled: December 16, 2003Publication date: June 22, 2006Applicant: ABBOTT GmbH & Co. KGInventors: Joerg Rosenberg, Matthias Degenhardt, Joerg Breitenbach, Tom Reiland, Kennan Marsh
-
Patent number: 7060822Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.Type: GrantFiled: July 24, 2000Date of Patent: June 13, 2006Assignee: Abbott GmbH & Co. KGInventors: Lee Arnold, Marina Moran Moset, Jose Maria Castellano Berlanga, Isabel Fernandez, David J. Calderwood, Paul Rafferty
-
Patent number: 7049312Abstract: Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2— R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent R3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.Type: GrantFiled: June 2, 2000Date of Patent: May 23, 2006Assignee: Abbott GmbH & Co. KGInventors: Paul Rafferty, David Calderwood, Lee Arnold, Beatriz Gonzalez Pascual, Jose L. Ortego Martinez, Maria J. Perez de Vega, Isabel Fernandez
-
Patent number: 7041675Abstract: The invention relates to compounds of the formula I and the tautomeric forms, possible enantiomeric and diasteromeric forms thereof, and prodrugs thereof, and use thereof as PARP inhibitors.Type: GrantFiled: January 25, 2001Date of Patent: May 9, 2006Assignee: Abbott GmbH & Co. KGInventors: Wilfried Lubisch, Michael Kock, Thomas Hoeger, Roland Grandel, Reinhold Mueller, Sabine Schult
-
Patent number: 7034158Abstract: The invention relates to a method for producing biperiden which is characterized in that an exo/endo mixture of 1-(bicyclo[2.2.1]hept-5-en-2-yl)-3-piperidino-1-propanone is reacted with an isomer ratio of the exo form to the endo form of at least 2.5:1 with diphenyl magnesium, an isomer mixture containing biperiden is obtained therefrom and biperiden is produced therefrom.Type: GrantFiled: May 17, 2002Date of Patent: April 25, 2006Assignee: Abbott GmbH & Co. KGInventors: Gerhard Kastner, Klaus Scheib
-
Patent number: 7026311Abstract: The invention relates to compounds of the formula I and their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their preparation and use, where A, B, R1 and X1 have the meanings given in the description.Type: GrantFiled: January 10, 2002Date of Patent: April 11, 2006Assignee: Abbott GmbH & Co., KGInventors: Wilfried Lubisch, Roland Grandel, Wilfried Braje, Thomas Subkowski, Reinhold Mueller, Wolfgang Wernet, Karla Drescher
-
Patent number: 7014810Abstract: The present invention relates to an apparatus for producing solid active ingredient-containing forms from an active ingredient-containing formulation which comprises at least one polymeric binder. The apparatus according to the invention has at least one extruder 1 for continuous plastication of the formulation and at least two injection units 2 which are provided separate from one another, each of which is connected to the extruder 1, and through which the formulation can be injected into at least one mold 3.Type: GrantFiled: December 15, 2000Date of Patent: March 21, 2006Assignee: Abbott GmbH & Co. KGInventors: Harald Krull, Jörg Rosenberg, Jörg Breitenbach, Jürgen Hofmann, Rainer Klenz, Hans Bührle
-
Patent number: 6992216Abstract: A method for reducing the particle size of amino acid crystals using ultrasound is discussed.Type: GrantFiled: January 7, 2003Date of Patent: January 31, 2006Assignee: Abbott GmbH & Co. KGInventors: Siegfried Bechtel, Matthias Rauls, Richard Van Gelder, Seth C. Simpson
-
Publication number: 20060009392Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K ??I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: ApplicationFiled: July 11, 2005Publication date: January 12, 2006Applicant: Abbott GMBH & Co., KG.Inventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weymann, Thomas Zierke
-
Patent number: 6919342Abstract: The invention relates to triazole compounds of the general formula I wherein R1 is hydrogen or methyl, and R2 is C3-C4 alkyl or C1-C2 fluoroalkyl, as well as the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.Type: GrantFiled: June 4, 2004Date of Patent: July 19, 2005Assignee: Abbott GmbH & Co. KGInventors: Andreas Haupt, Roland Grandel, Wilfried Braje, Hervé Geneste, Karla Drescher, Dorothea Starck, Hans-Jürgen Teschendorf
-
Patent number: 6914128Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 24, 2000Date of Patent: July 5, 2005Assignee: Abbott GmbH & Co. KGInventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Thor Las Holtet, Sarah Leila Du Fou, Stephen Smith